Table 2.

Dosage regimen of approved drugs for the treatment of adult glioblastoma. (Source: Dailymed/ Food and Drug Administration (FDA) label). RT: radiotherapy.

Therapeutic Agent	Disease Type	Dosage Regimen
Temozolomide (TMZ)	Newly diagnosed	Concurrent: 75 mg/m2 daily for six weeks with focal RT. Adjuvant *: Starts followed by a 4-week rest period after concurrent therapy. 1st cycle, 150 mg/m2 daily for five days in a 28-day cycle. 150–200 mg/m2 daily for 5 days in a 28-day cycle, 2nd–6th cycles.
Bevacizumab	Recurrent	10 mg/kg as intravenous infusion every 2 weeks **.
Carmustine (BiCNU) for injection	-	150–200 mg/m2 (single or divided into two successive days) intravenously every 6 weeks.
Carmustine (BiCNU) implant	Newly diagnosed/Recurrent	Eight 7.7 mg wafers with a total of 61.6 mg implanted intracranially.

* Dose could be reduced based on the appearance of toxicity. ** Treatment to be continued until disease progression or unacceptable toxicity.